Table 2.
Heterogeneity and meta-analysis of included studies.
| Items | Trials, n | Results | ||
|---|---|---|---|---|
| OR (95% CI) | p -value | Heterogeneity (I2, p for Cochran Q) | ||
| Poor outcome | 10 | 2.53 (1.99–3.22) | p < 0.00001 | I2 = 68%, P = 0.0008 |
| Mortality | 11 | 1.96 (1.58–2.44) | p < 0.00001 | I2 = 61%, P = 0.004 |
| Neurological deficit | 7 | 1.99 (1.47–2.70) | p < 0.00001 | I2 = 75%, P = 0.0005 |
| Hemorrhagic transformation | 7 | 3.70 (2.69–5.08) | p < 0.00001 | I2 = 0%, P = 0.69 |
| Pneumonia | 3 | 2.06 (1.57–2.72) | p < 0.00001 | I2 = 24%, P = 0.27 |
| Urinary tract infection | 2 | 2.53 (1.45–4.42) | p = 0.001 | I2 = 57%, P = 0.13 |
| Recanalization rate | 2 | 0.86 (0.54–2.04) | p = 0.53 | I2 = 0%, P = 0.32 |